[The use of recombinant interferon alfa-2b in the follow-up of patients laryngectomized for advanced stage carcinoma].
The AA. report the results of an experimental investigation on 60 subjects who underwent surgery for advanced stage carcinoma of the glottic larynx and treated with alpha 2b recombinant interferon at the dosage of 3,000,000 ul three times a week, before a six-months follow-up. The patients were examined also as to the respiratory functionality and the monitoring of some biological markers of cancers (CEA, TPA, Ca 125, Ca 15.3). The AA. support the satisfactory tolerability of alpha interferon which showed expected side effects; these effects were controlled by the symptomatic treatment, and their metabolic parameters as well as the ones related to the respiratory functionality kept always their valves in the average. The monitoring of biological markers, seems to support a real usefulness in the treatment with alpha interferon, even if a statistically meaningful record couldn't be noticed.
De Blasio
F
F
II Facoltà di Medicina e Chirurgia Insegnamento di Malattie dell'Apparato Respiratorio, Università degli Studi di Napoli Federico II.
Pepe
M
M
Sarno
M
M
Mormile
A F
AF
Pezza
A
A
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Utilizzo dell'interferone alfa 2b ricombinante nel follow-up di pazienti laringectomizzati per carcinoma in stadio avanzato.